Outcome of childhood relapsed or refractory mature B-cell non-Hodgkin lymphoma and acute lymphoblastic leukemia

References

• Cairo MS, Gerrard M, Sposto R, .; FAB/LMB96 International Study Committee. Results of a randomized international study of high-risk central nervous system B non-Hodgkin lymphoma and B acute lymphoblastic leukemia in children and adolescents. Blood 2007;109:2736–2743.
   PubMed Web of Science ®Google Scholar
• Patte C, Auperin A, Gerrard M, . FAB/LMB96 International Study Committee. Results of the randomized international FAB/LMB96 trial for intermediate risk B-cell non-Hodgkin lymphoma in children and adolescents: it is possible to reduce treatment for the early responding patients. Blood 2007;109:2773–2780.
   PubMed Web of Science ®Google Scholar
• Poirel HA, Cairo MS, Heerema NA, . Specific cytogenetic abnormalities are associated with a significantly inferior outcome in children and adolescents with mature B-cell non-Hodgkin's lymphoma: results of the FAB/LMB 96 international study. Leukemia 2009;23:323–331.
   PubMed Web of Science ®Google Scholar
• Atra A, Gerrard M, Hobson R, . Outcome of relapsed or refractory childhood B-cell acute lymphoblastic leukaemia and B-cell non-Hodgkin's lymphoma treated with the UKCCSG 9003/9002 protocols. Br J Haematol 2001;112:965–968.
   PubMed Web of Science ®Google Scholar
• Gerrard M, Cairo MS, Weston C, . FAB LMB96 International Study Committee. Excellent survival following two courses of COPAD chemotherapy in children and adolescents with resected localized B-cell non-Hodgkin's lymphoma: results of the FAB/LMB 96 international study. Br J Haematol 2008;141:840–847.
   PubMed Web of Science ®Google Scholar
• Attias D, Weitzman S. The efficacy of rituximab in high-grade pediatric B-cell lymphoma/leukemia: a review of available evidence. Curr Opin Pediatr 2008;20:17–22.
   PubMed Web of Science ®Google Scholar
• Attarbaschi A, Dworzak M, Steiner M, . Outcome of children with primary resistant or relapsed non-Hodgkin lymphoma and mature B-cell leukemia after intensive first-line treatment: a population-based analysis of the Austrian Cooperative Study Group. Pediatr Blood Cancer 2005;44:70–76.
   PubMed Web of Science ®Google Scholar
• Gross TG, Hale GA, He W, . Hematopoietic stem cell transplantation for refractory or recurrent non-Hodgkin lymphoma in children and adolescents. Biol Blood Marrow Transplant 2010;16:223–230.
   PubMed Web of Science ®Google Scholar
• Harris RE, Termuhlen AM, Smith LM, . Autologous peripheral blood stem cell transplantation in children with refractory or relapsed lymphoma: results of Children's Oncology Group study A5962. Biol Blood Marrow Transplant 2011;17:249–258.
   PubMed Web of Science ®Google Scholar
• Jaffe ES, Harris NL, Stein H, editors. World Health Organization classification of tumours. Pathology and genetics of tumours of haematopoietic and lymphoid tissues. Lyon: IARC Press; 2001.
   Google Scholar
• Murphy SB. Classification, staging and end results of treatment of childhood non-Hodgkin's lymphomas: dissimilarities from lymphomas in adults. Semin Oncol 1980;7:332–339.
   PubMed Web of Science ®Google Scholar
• UKCCSG NHL Group. Guidelines for the management of Burkitt/Burkitt-like and large B cell non-Hodgkin lymphoma. Sheffield: University of Sheffield Press; 2003.
   Google Scholar
• Cheson BD, Horning SJ, Coiffier B, . Report of an international workshop to standardize response criteria for non-Hodgkin's lymphomas. NCI Sponsored International Working Group. Clin Oncol 1999;17:1244–1253.
   Web of Science ®Google Scholar
• International standard randomised controlled trial number register [Internet]. NHL9602 trial. Available from: http://www.controlled-trials.com/isrctn25173819/nhl9602
   Google Scholar
• International standard randomised controlled trial number register [Internet]. NHL9603 trial. Available from: http://www.controlled-trials.com/isrctn25173819/nhl9603
   Google Scholar
• National Cancer Institute [Internet]. FAB/LMB96 clinical trial. Available from: http://www.cancer.gov/clinicaltrials/search/view?version=healthprofessional&cdrid= 64702#StudyIdInfo_CDR0000064702
   Google Scholar
• Keating GM. Rituximab: a review of its use in chronic lymphocytic leukaemia, low-grade or follicular lymphoma and diffuse large B-cell lymphoma. Drugs 2010;70:1445–1476.
   PubMed Web of Science ®Google Scholar
• Marcus R, Hagenbeek A. The therapeutic use of rituximab in non-Hodgkin's lymphoma. Eur J Haematol 2007;78(Suppl. 67):5–14.
   Web of Science ®Google Scholar
• Nademanee A, Molina A, Dagis A, . Autologous stem-cell transplantation for poor-risk and relapsed intermediate and high-grade non-Hodgkin's lymphoma. Clin Lymphoma 2000;1:46–54.
   PubMedGoogle Scholar
• Vose JM, Rizzo DJ, Tao-Wu J, . Autologous transplantation for diffuse aggressive non-Hodgkin lymphoma in first relapse or second remission. Biol Blood Marrow Transplant 2004;10:116–127.
   PubMed Web of Science ®Google Scholar
• Fujita N, Mori T, Mitsui T, . Lymphoma Committee of the Japanese Pediatric Leukemia/Lymphoma Study Group. The role of hematopoietic stem cell transplantation with relapsed or primary refractory childhood B-cell non-Hodgkin lymphoma and mature B-cell leukemia: a retrospective analysis of enrolled cases in Japan. Pediatr Blood Cancer 2008;51:188–192.
   PubMed Web of Science ®Google Scholar
• Griffin TC, Weitzman S, Weinstein H, . A study of rituximab and ifosfamide, carboplatin, and etoposide chemotherapy in children with recurrent/refractory B-cell (CD20 +) non-Hodgkin lymphoma and mature B-cell acute lymphoblastic leukemia: a report from the Children's Oncology Group. Pediatr Blood Cancer 2009;52:177–181.
   PubMed Web of Science ®Google Scholar